Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $1,588,920.00 in Stock

Key Points

• Martine Rothblatt, CEO of United Therapeutics, sold $1,588,920 in stock, significantly reducing their ownership by 96.85%, now holding only 130 shares.
• United Therapeutics stock is currently priced at $404.84, with a market capitalization of $18.26 billion, and a PE ratio of 15.80.
• The company reported $6.41 EPS in its latest quarter, missing estimates, but revenue increased by 11.7% compared to the previous year.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the company's stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $397.23, for a total transaction of $1,588,920.00. Following the transaction, the chief executive officer directly owned 130 shares of the company's stock, valued at $51,639.90. This trade represents a 96.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

United Therapeutics Stock Performance

United Therapeutics stock traded up $8.34 during midday trading on Thursday, reaching $404.84. The stock had a trading volume of 484,190 shares, compared to its average volume of 876,653. The stock's 50-day simple moving average is $314.12 and its 200 day simple moving average is $306.91. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $436.95. The stock has a market capitalization of $18.26 billion, a PE ratio of 15.80, a price-to-earnings-growth ratio of 6.05 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business's revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter last year, the business earned $5.85 earnings per share. Equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Oppenheimer lifted their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a research report on Friday, September 5th. Bank of America upped their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 2nd. JPMorgan Chase & Co. lowered their price target on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a report on Tuesday, July 8th. HC Wainwright boosted their price objective on United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research note on Friday, September 5th. Finally, Morgan Stanley lowered their target price on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $438.85.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of UTHR. XTX Topco Ltd purchased a new stake in United Therapeutics during the 1st quarter worth approximately $313,000. Allianz Asset Management GmbH grew its position in shares of United Therapeutics by 96.9% during the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after buying an additional 33,254 shares in the last quarter. LPL Financial LLC increased its stake in shares of United Therapeutics by 77.3% in the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock worth $7,783,000 after buying an additional 11,007 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in United Therapeutics by 11.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after acquiring an additional 376 shares in the last quarter. Finally, Concurrent Investment Advisors LLC bought a new position in United Therapeutics during the 1st quarter valued at $227,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.